Making Nerve Repair an Expected Standard of Care
A commitment to restoring health, improving quality of life, and advancing peripheral nerve care for every patient.
January 20216
Our Mission
To restore health and improve quality of life by making restoration of peripheral nerve function an expected standard
of care.
3
Large and Underserved $5.6B US Nerve Care Opportunity
More than 1.5 million peripheral nerve injuries a year require treatment in Axogen focus markets
Extremities Market
Breast Reconstruction
Oral, Maxillofacial & Head & Neck
Prostate Surgery
$2.9BEvery year patients suffer from 700,000 Traumatic Nerve Injuries and more than 370,000 Chronic nerve injuries.1
$677M1 of 8 women diagnosed with breast cancer. 80% of women experience pain, numbness or both after breast cancer surgery.2
$1.2BNerve damage caused by Oral Maxillofacial and H&N surgery is common and can result in loss of sensation and chronic pain.
$754M1 of 8 men diagnosed with prostate cancer. 25-90% experience Incontinence and Erectile Dysfunction (ED) Post robotic prostatectomy.3,4
Nerve injuries have a significant impact on patient's quality of life…
4
Common Types and Causes of Peripheral Nerve Injury
Neuroma
Cut or Laceration Compression Stretching
Trauma
Trauma that leads to damaged nerves
Severe Cuts, Falling Though Glass, Compression, Gunshot Wound, Blunt Trauma
Surgery
Nerves that have been cut, compressed or stretched during surgery
Mastectomy, Laparoscopy, Tumor Resection, Wrist or Knee Arthroscopy, Hip or Knee Arthroplasty
Amputation
Stump pain associated with nerve damage has been reported in over 68% of amputees5
Sensitivity to Touch, Residual Limb Pain, Burning Pain
5
The Axogen Nerve Repair Algorithm
Connection
Protection
Termination
6
Avance® is the First Approved Biologic Treatment for Repair of Nerve Discontinuities
in adult and pediatric patients aged one month and older
Preserves the delicate 3D macro and micro architecture of native nerve, which provides structural support for the regenerating axons
Bioactive laminin necessary for supporting neurite growth & axonal regeneration
Proprietary quality assays verify structural integrity & potency
NATIVE NERVE
7
Our Key Market Development Opportunities
Nerve Care is Not an Expected Standard of Care
Care guidelines and standardized treatment algorithms are lagging and to be developed for certain care pathways
Awareness of Treatment Options
Low patient and surgeon awareness of treatment options
Inefficient Patient Referral and Care Pathways
Approximately 60% of nerve injuries go undiagnosed prior to patient discharge6
Coverage & Payment
35% of commercial lives remain uncovered1
8
2025-2028 Strategic Plan Priorities Growth
CAGR 15 - 20%
MarketsElective and planned procedure focus
Prostate market development
Commercial ExpansionCommercial infrastructure and salesforce expansion
Commercial ExcellenceContinuous business model and customer creation process optimization by market
Standard of CareLevel 1 clinical evidence generation for societal support, standard of care & coverage requirements
InnovationProduct development to drive better benefit versus risk profiles in nerve care
9
Uniquely Positioned to Lead in Nerve Repair
Technology
Expertise
Access
AVANCE® (acellular nerve allograft-arwx) is the only FDA approved biologic nerve scaffold for treating peripheral nerve discontinuities
Axoguard® and Avive+
products for use across Axogen nerve repair algorithm
16 years of experience and
200,000+ patients treated
300+ clinical and scientific publications supporting our nerve repair algorithm
A valued educational partner committed to clinical science and innovation
Trusted partner to
6,500+ surgeons
Established access in more than 2,700 hospitals and outpatient centers, supported by the largest direct sales channel
10
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |